Thiadioxobenzodiazepine inhibitors of farnesyl protein...

C - Chemistry – Metallurgy – 07 – D

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07D 417/06 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) A61K 31/675 (2006.01) C07D 417/14 (2006.01) C07D 453/02 (2006.01) C07D 471/04 (2006.01) C07D 473/00 (2006.01) C07D 491/048 (2006.01) C07D 495/04 (2006.01) C07D 513/04 (2006.01) C07D 519/00 (2006.01) C07F 9/6558 (2006.01) C07F 9/6561 (2006.01)

Patent

CA 2260216

Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by coumpounds of formulas (I) and (II) and their enantiomers, diastereomers, and their pharmaceutically acceptable salts, including prodrugs and solvates thereof wherein: r, s and t are 0 or 1; m = 0, 1, 2; p is 0, 1 or 2; X is selected from the group consisting of oxygen, hydrogen or R1, R2, R3; Y is selected from the group consisting of CHR9, SO2, CO, CO2, O, NR10, SO2NR11 and CONR12; R6, R7, R9, R10, R11, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27 and R28 are selected from the group consisting of hydrogen, lower alkyl or substituted alkyl; R4, R5 are selected from the group consisting of hydrogen, halo, nitro, cyano and U-R13; R12 is selected from the group consisting of hydrogen, lower alkyl, aryl, substituted alkyl or aryl; U is selected from the group consisting of sulfur, oxygen, NR14, CO, SO, SO2, CO2, NR15CO2, NR16CONR17, NR18SO2, NR19SO2NR20, SO2NR21, NR22CO, CONR23, PO2R24 and PO3R25 or U is absent; R1, R2, R3, R8 and R13 are selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, cycloalkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo; R, S and T are selected from the group consisting of CH2, CO and CH(CH2)pQ wherein Q is NR26R27 or OR28; and A, B, C and D are carbon, oxygen, sulfur or nitrogen, with the proviso that R13 may be hydrogen except when U is SO, SO2, NR15CO2 or NR18SO2.

Inhibition de la farnésyle transférase, cette dernière étant une enzyme impliquée dans l'expression de l'oncogène ras. Cette inhibition est effectuée à l'aide des composés ayant les formules (I) et (II), et leurs énantiomères diastéréomères, et leur sels pharmaceutiquement acceptables, y compris des pro-médicaments et leurs solvates. Dans ces formules, r, s et t valent 0 ou 1; m = 0, 1, 2; p vaut 0, 1 ou 2; X est sélectionné dans le groupe comprenant oxygène, hydrogène ou R?1¿, R?2¿, R?3¿; Y est choisi dans le groupe comprenant CHR?9¿, SO¿2?, CO, CO¿2?, O, NR?10¿, SO¿2?, NR?11¿ et CONR?12¿; R?6¿, R?7¿, R?9¿, R?10¿, R?11¿, R?14¿, R?15¿, R?16¿, R?17¿, R?18¿, R?19¿, R?20¿, R?21¿, R?22¿, R?23¿, R?24¿, R?25¿, R?26¿, R?27¿ et R?28¿ sont choisis dans le groupe comprenant hydrogène, alkyle inférieur ou alkyle substitué; R?4¿ et R?5¿ sont choisis dans le groupe comprenant hydrogène, halo, nitro, cyano et U-R?13¿; R?12¿ est choisi dans le groupe comprenant hydrogène, alkyle inférieur, aryle, alkyle ou aryle substitués; U est choisi dans le groupe comprenant sulfure, oxygène, NR?14¿, CO, SO, SO¿2?, CO¿2?, NR?15¿, CO¿2?, NR?16¿, CONR?17¿, NR?18¿, SO¿2?, NR?19¿, SO¿2?, NR?20¿, SO¿2?, NR?21¿, NR?22¿, CO, CONR?23¿, PO¿2?, OR?24¿ et PO¿3?, R?25¿ ou U est absent; R?1¿, R?2¿, R?3¿, R?8¿ et R?13¿ sont choisis dans le groupe comprenant hydrogène, alkyle, alkyle substitué, alcényle, alcényle substitué, alcinyle, alcinyle substitué, aralkyle, cycloalkyle, aryle, aryle substitué, hétérocyclo, hétérocyclo substitué; R, S et T sont choisis dans le groupe comprenant CH¿2?, CO et CH(CH¿2?)¿p?Q où Q représente NR?26¿R?27¿ ou OR?28¿; et A, B, C et D représentent carbone, oxygène, soufre ou azote, à condition que R?13¿ soit hydrogène sauf lorsque U représente SO, SO¿2?, NR?15¿, CO¿2? ou NR?18¿, SO¿2?.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Thiadioxobenzodiazepine inhibitors of farnesyl protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiadioxobenzodiazepine inhibitors of farnesyl protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiadioxobenzodiazepine inhibitors of farnesyl protein... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1351068

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.